IL-11Rα Inhibitors

The chemical class of IL-11Rα Inhibitors includes a diverse array of specific compounds that can influence the signaling pathways crucial for IL-11Rα activity. Ruxolitinib and Stattic, targeting JAK and STAT3 pathways, respectively, potentially inhibit signaling processes crucial for IL-11Rα-mediated responses. BAY 11-7082, an NF-kappaB inhibitor, and SB431542, a TGF-beta signaling inhibitor, can modulate broader inflammatory and proliferative pathways that might intersect with IL-11Rα signaling.

LY294002 and Everolimus, inhibitors of the PI3K/AKT and mTOR pathways, respectively, can affect cell proliferation and immune response pathways, potentially influencing IL-11Rα activity. Prednisone, a glucocorticoid, might modulate immune responses and downregulate IL-11Rα in certain contexts. Trichostatin A, an HDAC inhibitor, and Imatinib, a tyrosine kinase inhibitor, can alter cell signaling and gene expression, potentially leading to reduced IL-11Rα activity. Cyclosporine A and Bortezomib are also included for their roles in modulating immune signaling and proteasome function, respectively, which could indirectly impact IL-11Rα.